• NeuroSense Therapeutics (NRSN) is trading up 1.58% today at $0.77 following the announcement of positive biomarker findings from its Phase 2 study of PrimeC in Alzheimer's disease.
  • The study revealed distinctive protein biomarker changes, including hallmark proteins of Alzheimer's disease (brain-derived tau, phospho-tau, amyloid-beta ratio), aligning with PrimeC's proposed mechanism of action.
  • This significant positive development provides a clear company-specific catalyst for today's stock movement.